Please use this identifier to cite or link to this item:
https://doi.org/10.1186/s12943-017-0596-9
| Title: | Epigenetics in cancer stem cells | Authors: | Toh, T.B Lim, J.J Chow, E.K.-H |
Keywords: | beta catenin DNA DNA methyltransferase histone histone deacetylase histone demethylase histone methyltransferase Notch receptor sonic hedgehog protein Wnt protein antineoplastic agent DNA (cytosine 5) methyltransferase histone cancer growth cancer stem cell carcinogenesis DNA methylation drug resistance epigenetics epithelial mesenchymal transition genetic regulation histone acetylation histone demethylation histone methylation human metastasis nonhuman Review signal transduction acetylation animal antagonists and inhibitors cancer stem cell drug effects genetic epigenesis genetics metabolism methylation Neoplasms pathology procedures Acetylation Animals Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols DNA (Cytosine-5-)-Methyltransferase DNA Methylation Drug Resistance, Neoplasm Epigenesis, Genetic Epigenomics Histones Humans Methylation Neoplasm Metastasis Neoplasms Neoplastic Stem Cells Signal Transduction |
Issue Date: | 2017 | Citation: | Toh, T.B, Lim, J.J, Chow, E.K.-H (2017). Epigenetics in cancer stem cells. Molecular Cancer 16 (1) : 29. ScholarBank@NUS Repository. https://doi.org/10.1186/s12943-017-0596-9 | Rights: | Attribution 4.0 International | Abstract: | Compelling evidence have demonstrated that bulk tumors can arise from a unique subset of cells commonly termed "cancer stem cells" that has been proposed to be a strong driving force of tumorigenesis and a key mechanism of therapeutic resistance. Recent advances in epigenomics have illuminated key mechanisms by which epigenetic regulation contribute to cancer progression. In this review, we present a discussion of how deregulation of various epigenetic pathways can contribute to cancer initiation and tumorigenesis, particularly with respect to maintenance and survival of cancer stem cells. This information, together with several promising clinical and preclinical trials of epigenetic modulating drugs, offer new possibilities for targeting cancer stem cells as well as improving cancer therapy overall. © 2017 The Author(s). | Source Title: | Molecular Cancer | URI: | https://scholarbank.nus.edu.sg/handle/10635/181300 | ISSN: | 14764598 | DOI: | 10.1186/s12943-017-0596-9 | Rights: | Attribution 4.0 International |
| Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
| File | Description | Size | Format | Access Settings | Version | |
|---|---|---|---|---|---|---|
| 10_1186_s12943-017-0596-9.pdf | 866.57 kB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License
